Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients-Reference-Cited by-同舟云学术

Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients

Published:2013-11 Issue:5 Volume:42 Page:384-389
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Adnan Syamhanin,Paterson David L.,Lipman Jeffrey,Roberts Jason A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference75 articles.

1. US Food and Drug Administration. Unasyn (ampicillin/sulbactam): detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—April 2008.

2. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009);Hawser;Clin Microbiol Infect,2011

3. Clinical characteristics of bloodstream infections due to ampicillin–sulbactam-resistant, non-extended-spectrum-β-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction;Waltner-Toews;Antimicrob Agents Chemother,2011

4. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam;Levin;Int J Antimicrob Agents,2003

5. High-dose ampicillin–sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii;Betrosian;Scand J Infect Dis,2007

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections;Infection;2024-07-23

2. Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations;Journal of Antimicrobial Chemotherapy;2024-07-20

3. Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy;Journal of Antimicrobial Chemotherapy;2024-07-13

4. Parenteral medication use in hospital at home: Challenges and opportunities;American Journal of Health-System Pharmacy;2024-05-28

5. A retrospective study of the efficacy of sulbactam in the treatment of patients with extensively drug-resistant Acinetobacter baumannii infections;2024-04-10